- Home
- HYFT vs IMA Comparison
HYFT vs IMA Comparison
Compare HYFT & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYFT | IMA |
|---|---|---|
| Founded | 1983 | 2019 |
| Country | United States | United States |
| Employees | 77 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.5M | 66.3M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HYFT | IMA |
|---|---|---|
| Price | $1.16 | $4.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $4.33 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 280.8K | 10.7K |
| Earning Date | 09-14-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | $12.86 | N/A |
| Revenue Next Year | $22.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.99 | $3.90 |
| 52 Week High | $3.00 | $9.10 |
Technical Indicators
Market Signals| Indicator | HYFT | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 36.43 | 30.51 |
| Support Level | $1.03 | $3.92 |
| Resistance Level | $1.46 | $6.13 |
| Average True Range (ATR) | 0.12 | 0.19 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 5.61 | 21.95 |
Price Performance
Historical ComparisonAbout HYFT MindWalk Holdings Corp.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.